Comparative Pharmacology
Head-to-head clinical analysis: BUTABARB versus BUTABARBITAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTABARB versus BUTABARBITAL SODIUM.
BUTABARB vs BUTABARBITAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.
Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.
15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.
Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.
None Documented
None Documented
Clinical Note
moderateButabarbital + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone propionate."
Clinical Note
moderateButabarbital + Haloperidol
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol."
Clinical Note
moderateButabarbital + Clemastine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Clemastine."
Clinical Note
moderateTerminal elimination half-life is 30-60 hours (mean ~40 hours) in adults with normal renal and hepatic function. Longer in elderly or patients with liver disease.
Terminal elimination half-life: 30-50 hours; accumulates with repeated dosing, prolonged in hepatic impairment
Renal excretion of unchanged drug and metabolites. Approximately 70-80% of a dose is eliminated in urine as metabolites (hydroxy and glucuronide conjugates) and <5% as parent drug. Minimal biliary/fecal elimination (<5%).
Renal: 50-70% as metabolites (hydroxylated and conjugated forms), 5-10% unchanged; fecal: minor (<5%)
Category C
Category C
Barbiturate
Barbiturate
Butabarbital + Venlafaxine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Venlafaxine."